Journal Article
. 2006 Jun;8(3).
doi: 10.1186/bcr1412.

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

Laurel A Habel 1 Steven Shak  Marlena K Jacobs  Angela Capra  Claire Alexander  Mylan Pho  Joffre Baker  Michael Walker  Drew Watson  James Hackett  Noelle T Blick  Deborah Greenberg  Louis Fehrenbacher  Bryan Langholz  Charles P Quesenberry  
Affiliations
  • PMID: 16737553
  •     40 References
  •     157 citations

Abstract

Introduction: The Oncotype DX assay was recently reported to predict risk for distant recurrence among a clinical trial population of tamoxifen-treated patients with lymph node-negative, estrogen receptor (ER)-positive breast cancer. To confirm and extend these findings, we evaluated the performance of this 21-gene assay among node-negative patients from a community hospital setting.

Methods: A case-control study was conducted among 4,964 Kaiser Permanente patients diagnosed with node-negative invasive breast cancer from 1985 to 1994 and not treated with adjuvant chemotherapy. Cases (n = 220) were patients who died from breast cancer. Controls (n = 570) were breast cancer patients who were individually matched to cases with respect to age, race, adjuvant tamoxifen, medical facility and diagnosis year, and were alive at the date of death of their matched case. Using an RT-PCR assay, archived tumor tissues were analyzed for expression levels of 16 cancer-related and five reference genes, and a summary risk score (the Recurrence Score) was calculated for each patient. Conditional logistic regression methods were used to estimate the association between risk of breast cancer death and Recurrence Score.

Results: After adjusting for tumor size and grade, the Recurrence Score was associated with risk of breast cancer death in ER-positive, tamoxifen-treated and -untreated patients (P = 0.003 and P = 0.03, respectively). At 10 years, the risks for breast cancer death in ER-positive, tamoxifen-treated patients were 2.8% (95% confidence interval [CI] 1.7-3.9%), 10.7% (95% CI 6.3-14.9%), and 15.5% (95% CI 7.6-22.8%) for those in the low, intermediate and high risk Recurrence Score groups, respectively. They were 6.2% (95% CI 4.5-7.9%), 17.8% (95% CI 11.8-23.3%), and 19.9% (95% CI 14.2-25.2%) for ER-positive patients not treated with tamoxifen. In both the tamoxifen-treated and -untreated groups, approximately 50% of patients had low risk Recurrence Score values.

Conclusion: In this large, population-based study of lymph node-negative patients not treated with chemotherapy, the Recurrence Score was strongly associated with risk of breast cancer death among ER-positive, tamoxifen-treated and -untreated patients.

Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology.
N Krieger.
Am J Public Health, 1992 May 01; 82(5). PMID: 1566949    Free PMC article.
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Histological grading of breast carcinomas: a study of interobserver agreement.
P Robbins, S Pinder, +5 authors, C Elston.
Hum Pathol, 1995 Aug 01; 26(8). PMID: 7635449
Highly Cited.
Estimation of absolute risk from nested case-control data.
B Langholz, O Borgan.
Biometrics, 1997 Jun 01; 53(2). PMID: 9192463
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 Sep 30; 352(9132). PMID: 9752815
Highly Cited.
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
J M Harvey, G M Clark, C K Osborne, D C Allred.
J Clin Oncol, 1999 May 20; 17(5). PMID: 10334533
Highly Cited.
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
J Chang, T J Powles, +7 authors, M Dowsett.
J Clin Oncol, 1999 Oct 03; 17(10). PMID: 10506600
Gene expression profiling of primary breast cancer.
Roman Rouzier, Peter Wagner, Paolo Morandi, Lajos Pusztai.
Curr Oncol Rep, 2004 Dec 22; 7(1). PMID: 15610685
Review.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Individualized care for patients with cancer - a work in progress.
Robert C Bast, Gabriel N Hortobagyi.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591336
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Gene expression profiling of primary breast carcinomas using arrays of candidate genes.
F Bertucci, R Houlgatte, +9 authors, C Nguyen.
Hum Mol Genet, 2000 Dec 15; 9(20). PMID: 11115842
Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women.
S Demissie, R A Silliman, T L Lash.
J Clin Oncol, 2001 Feb 24; 19(2). PMID: 11208822
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
P Eifel, J A Axelson, +11 authors, D Roter.
J Natl Cancer Inst, 2001 Jul 05; 93(13). PMID: 11438563
Highly Cited. Review.
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.
A Goldhirsch, J H Glick, +2 authors, H J Senn.
J Clin Oncol, 2001 Sep 18; 19(18). PMID: 11559719
Review.
NCCN: Breast cancer.
R W Carlson, S B Edge, R L Theriault, NCCN Breast Cancer Practice Guidelines Panel.
Cancer Control, 2002 Jan 05; 8(6 Suppl 2). PMID: 11760559
Review.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Adjuvant therapy for breast cancer: practice patterns of community physicians.
Linda C Harlan, Jeffrey Abrams, +3 authors, Rachel Ballard-Barbash.
J Clin Oncol, 2002 Mar 29; 20(7). PMID: 11919238
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
Ann H Partridge, Philip S Wang, Eric P Winer, Jerry Avorn.
J Clin Oncol, 2003 Feb 15; 21(4). PMID: 12586795
Highly Cited.
Gene expression predictors of breast cancer outcomes.
Erich Huang, Skye H Cheng, +10 authors, Andrew T Huang.
Lancet, 2003 May 16; 361(9369). PMID: 12747878
Highly Cited.
Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
Christos Sotiriou, Soek-Ying Neo, +7 authors, Edison T Liu.
Proc Natl Acad Sci U S A, 2003 Aug 15; 100(18). PMID: 12917485    Free PMC article.
Highly Cited.
Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.
Maureen Cronin, Mylan Pho, +5 authors, Joffre B Baker.
Am J Pathol, 2003 Dec 26; 164(1). PMID: 14695316    Free PMC article.
Highly Cited.
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes.
Jennifer Pittman, Erich Huang, +9 authors, Mike West.
Proc Natl Acad Sci U S A, 2004 May 21; 101(22). PMID: 15152076    Free PMC article.
Trends in breast cancer by race and ethnicity.
Asma Ghafoor, Ahmedin Jemal, +3 authors, Michael Thun.
CA Cancer J Clin, 2004 Jul 01; 53(6). PMID: 15224974
Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.
Aliza K Fink, Jerry Gurwitz, +2 authors, Rebecca A Silliman.
J Clin Oncol, 2004 Aug 18; 22(16). PMID: 15310774
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Bernard Fisher, Jong-Hyeon Jeong, +5 authors, National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Lancet, 2004 Sep 08; 364(9437). PMID: 15351193
The frequency of kidney and urinary tract diseases in a defined population.
R A Hiatt, G D Friedman.
Kidney Int, 1982 Jul 01; 22(1). PMID: 6181284
Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis.
B W Davis, R D Gelber, +7 authors, I Russell.
Cancer, 1986 Dec 15; 58(12). PMID: 3536070
Observer variation in histological grading of breast cancer.
D S Hopton, J Thorogood, A D Clayden, D MacKinnon.
Eur J Surg Oncol, 1989 Feb 01; 15(1). PMID: 2645174
Histological grading of breast cancer. Interobserver, reproducibility and prognostic significance.
F Theissig, K D Kunze, G Haroske, W Meyer.
Pathol Res Pract, 1990 Dec 01; 186(6). PMID: 1964730
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
C W Elston, I O Ellis.
Histopathology, 1991 Nov 01; 19(5). PMID: 1757079
Highly Cited.
Long-term complications of adjuvant chemotherapy for early stage breast cancer.
Ann H Partridge, Eric P Winer.
Breast Dis, 2005 Feb 03; 21. PMID: 15687723
Review.
Lessons from controversy: ovarian cancer screening and serum proteomics.
David F Ransohoff.
J Natl Cancer Inst, 2005 Feb 17; 97(4). PMID: 15713968
Genomic approaches in the management and treatment of breast cancer.
J C Chang, S G Hilsenbeck, S A W Fuqua.
Br J Cancer, 2005 Feb 17; 92(4). PMID: 15714204    Free PMC article.
Review.
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Francisco J Esteva, Aysegul A Sahin, +8 authors, Gabriel N Hortobagyi.
Clin Cancer Res, 2005 May 04; 11(9). PMID: 15867229
Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index.
John S Meyer, Consuelo Alvarez, +8 authors, Cooperative Breast Cancer Tissue Resource.
Mod Pathol, 2005 May 28; 18(8). PMID: 15920556
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Luca Gianni, Milvia Zambetti, +14 authors, Steven Shak.
J Clin Oncol, 2005 Sep 08; 23(29). PMID: 16145055
Highly Cited.
When is a genomic classifier ready for prime time?
Richard Simon.
Nat Clin Pract Oncol, 2005 Nov 03; 1(1). PMID: 16264774
Review.
Some evidence refuting the HMO "favorable selection" hypothesis: the case of Kaiser Permanente.
N P Gordon, G A Kaplan.
Adv Health Econ Health Serv Res, 1990 Dec 10; 12. PMID: 10122802
An overview of prognostic factors for long-term survivors of breast cancer.
Isabelle Soerjomataram, Marieke W J Louwman, +2 authors, Jan Willem W Coebergh.
Breast Cancer Res Treat, 2007 Mar 23; 107(3). PMID: 17377838    Free PMC article.
Highly Cited. Review.
Is the thymidine labeling index a good prognostic marker in breast cancer?
Ebru Sen-Oran, Vahit Ozmen, +5 authors, Mustafa Kecer.
World J Surg Oncol, 2007 Aug 21; 5. PMID: 17705874    Free PMC article.
Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer.
Alison K Conlin, Andrew D Seidman.
Mol Diagn Ther, 2007 Dec 15; 11(6). PMID: 18078353
Review.
Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
Jan Franko, Alyssa M Krasinskas, +6 authors, A James Moser.
J Gastrointest Surg, 2008 Aug 05; 12(10). PMID: 18677542
Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
Yujin Hoshida, Augusto Villanueva, +25 authors, Todd R Golub.
N Engl J Med, 2008 Oct 17; 359(19). PMID: 18923165    Free PMC article.
Highly Cited.
Current research topics in endocrine therapy for breast cancer.
Hiroko Yamashita.
Int J Clin Oncol, 2008 Oct 24; 13(5). PMID: 18946747
Review.
Gene expression profiling of breast cancer.
Ting Bao, Nancy E Davidson.
Adv Surg, 2008 Oct 29; 42. PMID: 18953822    Free PMC article.
Review.
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
Genet Med, 2009 Jan 07; 11(1). PMID: 19125125    Free PMC article.
Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics.
P D Williams, J K Lee, D Theodorescu.
Curr Oncol, 2009 Feb 21; 16(1). PMID: 19229372    Free PMC article.
A radiation-derived gene expression signature predicts clinical outcome for breast cancer patients.
Brian D Piening, Pei Wang, Aravind Subramanian, Amanda G Paulovich.
Radiat Res, 2009 Mar 10; 171(2). PMID: 19267539    Free PMC article.
Factors influencing the statistical power of complex data analysis protocols for molecular signature development from microarray data.
Constantin F Aliferis, Alexander Statnikov, +3 authors, Frank E Harrell.
PLoS One, 2009 Mar 18; 4(3). PMID: 19290050    Free PMC article.
Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer.
Attila Tordai, Cornelia Liedtke, Lajos Pusztai.
Clin Exp Metastasis, 2009 Apr 22; 26(7). PMID: 19381845
Review.
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.
Catherine Oakman, Silvia Bessi, +3 authors, Angelo Di Leo.
Breast Cancer Res, 2009 May 14; 11(2). PMID: 19435470    Free PMC article.
Review.
Genomic predictors of outcome and treatment response in breast cancer.
Lara Dunn, Angela Demichele.
Mol Diagn Ther, 2009 Jun 23; 13(2). PMID: 19537843
Review.
Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer.
Enrique Espinosa, Iker Sánchez-Navarro, +9 authors, Juan Angel Fresno Vara.
PLoS One, 2009 Jun 24; 4(6). PMID: 19547727    Free PMC article.
Verification of a prolonged untreated natural history of breast cancer by the multigene assay.
Tadeja Urbas, Neal Agee, Marcia E Bouton, Ian K Komenaka.
Med Oncol, 2009 Jun 24; 27(3). PMID: 19548125
Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer.
Steven Buechler.
BMC Cancer, 2009 Jul 22; 9. PMID: 19619298    Free PMC article.
Genetic characterization of breast cancer and implications for clinical management.
Felipe C Geyer, Maria A Lopez-Garcia, Maryou B Lambros, Jorge S Reis-Filho.
J Cell Mol Med, 2009 Sep 17; 13(10). PMID: 19754664    Free PMC article.
Review.
Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications.
Lap Ho, Hayley Fivecoat, Jun Wang, Giulio Maria Pasinetti.
Exp Gerontol, 2009 Oct 03; 45(1). PMID: 19796674    Free PMC article.
Review.
Cryotherapy for breast cancer: a feasibility study without excision.
Peter J Littrup, Bassel Jallad, +3 authors, David Bouwman.
J Vasc Interv Radiol, 2009 Oct 06; 20(10). PMID: 19800542    Free PMC article.
Histological and molecular types of breast cancer: is there a unifying taxonomy?
Britta Weigelt, Jorge S Reis-Filho.
Nat Rev Clin Oncol, 2009 Nov 28; 6(12). PMID: 19942925
Highly Cited. Review.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Review of the clinical studies using the 21-gene assay.
Catherine M Kelly, Ellen Warner, +2 authors, Kathleen I Pritchard.
Oncologist, 2010 Apr 28; 15(5). PMID: 20421266    Free PMC article.
Review.
Molecular markers to individualize adjuvant therapy for colon cancer.
Tara Gangadhar, Richard L Schilsky.
Nat Rev Clin Oncol, 2010 May 05; 7(6). PMID: 20440283
Review.
Gene-expression-based prognostic assays for breast cancer.
Chungyeul Kim, Soonmyung Paik.
Nat Rev Clin Oncol, 2010 May 05; 7(6). PMID: 20440284
Review.
Unraveling human complexity and disease with systems biology and personalized medicine.
Stephen Naylor, Jake Y Chen.
Per Med, 2010 Jun 26; 7(3). PMID: 20577569    Free PMC article.
Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach.
Mohamed M Desouki, Shaoxi Liao, +5 authors, Joseph Geradts.
J Cancer Res Clin Oncol, 2010 Aug 04; 137(5). PMID: 20680643
Gene-expression profiling in breast cancer: bespoke cancer therapy or more fiction than science?
M Barry, M R Kell.
Ir J Med Sci, 2010 Sep 03; 179(4). PMID: 20809382
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.
Ruth Oratz, Dev Paul, Allen L Cohn, Scot M Sedlacek.
J Oncol Pract, 2007 Jul 01; 3(4). PMID: 20859407    Free PMC article.
Tumor gene expression profiling in women with breast cancer. Test category: prognostic.
Cecelia Bellcross, W David Dotson.
PLoS Curr, 2010 Sep 30; 2. PMID: 20877449    Free PMC article.
Should Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas?
Mathew Purdom, Michael L Cibull, +4 authors, Rouzan G Karabakhtsian.
Patholog Res Int, 2010 Dec 15; 2011. PMID: 21151541    Free PMC article.
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning.
Min Yi, Thomas A Buchholz, +12 authors, Kelly K Hunt.
Ann Surg, 2011 Jan 07; 253(3). PMID: 21209588    Free PMC article.
Postoperative fever: the potential relationship with prognosis in node negative breast cancer patients.
Tingting Yan, Wenjin Yin, +4 authors, Jinsong Lu.
PLoS One, 2011 Jan 07; 5(12). PMID: 21209958    Free PMC article.
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.
Pierre-Emmanuel Colombo, Fernanda Milanezi, Britta Weigelt, Jorge S Reis-Filho.
Breast Cancer Res, 2011 Jul 27; 13(3). PMID: 21787441    Free PMC article.
Review.
Histopathological and genomic grading provide complementary prognostic information in breast cancer: a study on publicly available datasets.
Nilotpal Chowdhury.
Patholog Res Int, 2011 Aug 17; 2011. PMID: 21845210    Free PMC article.
Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
Robin K Kelley, Alan P Venook.
Clin Colorectal Cancer, 2011 Aug 24; 10(2). PMID: 21859557    Free PMC article.
Review.
Do all patients with breast cancer require systemic adjuvant therapy?
Jennifer J Griggs, Daniel F Hayes.
J Natl Cancer Inst, 2011 Sep 02; 103(18). PMID: 21881041    Free PMC article.
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
Gong Tang, Jack Cuzick, +6 authors, Norman Wolmark.
J Clin Oncol, 2011 Oct 20; 29(33). PMID: 22010013    Free PMC article.
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Jennifer E Joh, Nicole N Esposito, +10 authors, Geza Acs.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016474    Free PMC article.
Practical implications of gene-expression-based assays for breast oncologists.
Aleix Prat, Matthew J Ellis, Charles M Perou.
Nat Rev Clin Oncol, 2011 Dec 07; 9(1). PMID: 22143140    Free PMC article.
Highly Cited. Review.
Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?
Donna H Odierna, Aimee Afable-Munsuz, +5 authors, Ninez A Ponce.
Per Med, 2011 Dec 23; 8(6). PMID: 22190978    Free PMC article.
Gene expression profiling: changing face of breast cancer classification and management.
Robert Wesolowski, Bhuvaneswari Ramaswamy.
Gene Expr, 2012 Jan 25; 15(3). PMID: 22268293    Free PMC article.
Review.
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.
Katrina A B Goddard, William A Knaus, +8 authors, David L Veenstra.
Genet Med, 2012 Apr 21; 14(7). PMID: 22516979    Free PMC article.
Review.
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
S Barton, L Zabaglo, +6 authors, M Dowsett.
Br J Cancer, 2012 Apr 26; 106(11). PMID: 22531639    Free PMC article.
Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?
Jeffrey G Schneider, Danny N Khalil.
Breast Cancer Res Treat, 2012 Jun 23; 134(3). PMID: 22723033    Free PMC article.
Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis.
Masoud H Manjili, Kayvan Najarian, Xiang-Yang Wang.
Future Oncol, 2012 Jul 07; 8(6). PMID: 22764768    Free PMC article.
Review.
Whole transcriptome RNA-Seq analysis of breast cancer recurrence risk using formalin-fixed paraffin-embedded tumor tissue.
Dominick Sinicropi, Kunbin Qu, +14 authors, Joffre Baker.
PLoS One, 2012 Jul 19; 7(7). PMID: 22808097    Free PMC article.
Understanding how breast cancer patients use risk information from genomic tests.
Jessica T DeFrank, Lisa A Carey, Noel T Brewer.
J Behav Med, 2012 Aug 11; 36(6). PMID: 22878783    Free PMC article.
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat.
Ont Health Technol Assess Ser, 2010 Jan 01; 10(23). PMID: 23074401    Free PMC article.
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
W Eiermann, M Rezai, +13 authors, J Blohmer.
Ann Oncol, 2012 Nov 09; 24(3). PMID: 23136233    Free PMC article.
Barriers to the use of personalized medicine in breast cancer.
Christine B Weldon, Julia R Trosman, +2 authors, Julian C Schink.
J Oncol Pract, 2012 Nov 28; 8(4). PMID: 23180995    Free PMC article.
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients.
Michael R Mallmann, Andrea Staratschek-Jox, +5 authors, Joachim L Schultze.
EPMA J, 2010 Sep 01; 1(3). PMID: 23199086    Free PMC article.
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.
H A Azim, S Michiels, +9 authors, C Swanton.
Ann Oncol, 2013 Jan 23; 24(3). PMID: 23337633    Free PMC article.
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
Laurel A Habel, Lori C Sakoda, +6 authors, Charles P Quesenberry.
Breast Cancer Res, 2013 Mar 19; 15(2). PMID: 23497539    Free PMC article.
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
Zsuzsanna Varga, Peter Sinn, +6 authors, Holger Moch.
PLoS One, 2013 Mar 19; 8(3). PMID: 23505515    Free PMC article.
Gene expression profiling in breast cancer.
Belisario A Arango, Celine L Rivera, Stefan Glück.
Am J Transl Res, 2013 Apr 11; 5(2). PMID: 23573359    Free PMC article.
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Lawrence J Solin, Robert Gray, +13 authors, Sunil Badve.
J Natl Cancer Inst, 2013 May 04; 105(10). PMID: 23641039    Free PMC article.
Highly Cited.
The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
Salomon M Stemmer, Shmuel H Klang, +7 authors, Nicky Lieberman.
Breast Cancer Res Treat, 2013 Jun 27; 140(1). PMID: 23801158    Free PMC article.
Adopting nested case-control quota sampling designs for the evaluation of risk markers.
Yingye Zheng, Tianxi Cai, Margaret S Pepe.
Lifetime Data Anal, 2013 Jun 29; 19(4). PMID: 23807695    Free PMC article.
Cellular iron metabolism in prognosis and therapy of breast cancer.
Suzy V Torti, Frank M Torti.
Crit Rev Oncog, 2013 Jul 25; 18(5). PMID: 23879588    Free PMC article.
Review.
Who gets genomic testing for breast cancer recurrence risk?
J T DeFrank, T Salz, K Reeder-Hayes, N T Brewer.
Public Health Genomics, 2013 Aug 01; 16(5). PMID: 23899493    Free PMC article.
Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Clara Chen, Rahul Dhanda, +2 authors, Debra A Patt.
J Oncol Pract, 2013 Aug 15; 9(4). PMID: 23942918    Free PMC article.
Benefits, issues, and recommendations for personalized medicine in oncology in Canada.
C Butts, S Kamel-Reid, +9 authors, F D Ashbury.
Curr Oncol, 2013 Oct 25; 20(5). PMID: 24155644    Free PMC article.
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.
Lisa M McShane, Margaret M Cavenagh, +12 authors, Barbara A Conley.
BMC Med, 2013 Nov 16; 11. PMID: 24228635    Free PMC article.
The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy.
Nava Siegelmann-Danieli, Barbara Silverman, +3 authors, Avi Porath.
Ecancermedicalscience, 2014 Jan 05; 7. PMID: 24386009    Free PMC article.
Breast Cancer Biomarkers: Utility in Clinical Practice.
Fanny Le Du, Naoto T Ueno, Ana M Gonzalez-Angulo.
Curr Breast Cancer Rep, 2014 Jan 15; 5(4). PMID: 24416469    Free PMC article.
The application of Oncotype DX in early-stage lymph-node-positive disease.
Sarika Jain, William J Gradishar.
Curr Oncol Rep, 2014 Jan 21; 16(1). PMID: 24442572
Review.
Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
Carol Sweeney, Philip S Bernard, +11 authors, Bette J Caan.
Cancer Epidemiol Biomarkers Prev, 2014 Feb 14; 23(5). PMID: 24521995    Free PMC article.
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Review.
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results.
Georgeta Fried, Mor Moskovitz.
Springerplus, 2014 Feb 26; 3. PMID: 24567880    Free PMC article.
Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
Kristin Jonsdottir, Jörg Assmus, +4 authors, Emiel A M Janssen.
PLoS One, 2014 Mar 07; 9(3). PMID: 24599057    Free PMC article.
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow.
Bahriye Aktas, Agnes Bankfalvi, +2 authors, Sabine Kasimir-Bauer.
Mol Clin Oncol, 2014 Mar 22; 1(6). PMID: 24649291    Free PMC article.
Future directions for the early detection of recurrent breast cancer.
Erika J Schneble, Lindsey J Graham, +10 authors, Robert F Setlik.
J Cancer, 2014 May 03; 5(4). PMID: 24790657    Free PMC article.
Review.
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Adam M Brufsky.
Am J Clin Oncol, 2014 May 24; 37(4). PMID: 24853663    Free PMC article.
Systematic Review.
Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.
Thomas E Rohan, Xiaonan Xue, +10 authors, Joan G Jones.
J Natl Cancer Inst, 2014 Jun 05; 106(8). PMID: 24895374    Free PMC article.
Highly Cited.
Atomic force microscopic detection enabling multiplexed low-cycle-number quantitative polymerase chain reaction for biomarker assays.
Andrey Mikheikin, Anita Olsen, +3 authors, Jason Reed.
Anal Chem, 2014 Jun 12; 86(13). PMID: 24918650    Free PMC article.
Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer.
Alex Farr, Rachel Wuerstlein, +2 authors, Nadia Harbeck.
Rev Obstet Gynecol, 2013 Jan 01; 6(3-4). PMID: 24920978    Free PMC article.
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Laura Zanotti, Alberto Bottini, +2 authors, Maria Rosa Cappelletti.
Tumour Biol, 2014 Jul 23; 35(9). PMID: 25048969
Review.
Genome-based risk prediction for early stage breast cancer.
Christina Adaniel, Komal Jhaveri, Adriana Heguy, Francisco J Esteva.
Oncologist, 2014 Sep 05; 19(10). PMID: 25187476    Free PMC article.
Review.
Automated quantification of aligned collagen for human breast carcinoma prognosis.
Jeremy S Bredfeldt, Yuming Liu, +3 authors, Kevin W Eliceiri.
J Pathol Inform, 2014 Sep 25; 5(1). PMID: 25250186    Free PMC article.
Highly Cited.
A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer.
Steven E Canfield, Adam S Kibel, +3 authors, Judd W Moul.
Rev Urol, 2014 Dec 31; 16(4). PMID: 25548544    Free PMC article.
Clinical utility of gene expression profiling data for clinical decision-making regarding adjuvant therapy in early stage, node-negative breast cancer: a case report.
Steven R Schuster, Barbara A Pockaj, +2 authors, Donald W Northfelt.
J Pers Med, 2012 Jan 01; 2(3). PMID: 25562201    Free PMC article.
Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.
Purificacion Estevez-Garcia, Fernando Rivera, +8 authors, Rocio Garcia-Carbonero.
Oncotarget, 2015 Mar 03; 6(8). PMID: 25730906    Free PMC article.
The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment.
Yvonne Bombard, Linda Rozmovits, +3 authors, Deborah A Marshall.
Oncologist, 2015 Mar 10; 20(4). PMID: 25746345    Free PMC article.
Comprehensive molecular screening: from the RT-PCR to the RNA-seq.
Carlota Costa, Ana Giménez-Capitán, Niki Karachaliou, Rafael Rosell.
Transl Lung Cancer Res, 2013 Apr 01; 2(2). PMID: 25806219    Free PMC article.
Review.
Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.
Elizabeth J Sutton, Jung Hun Oh, +5 authors, Elizabeth A Morris.
J Magn Reson Imaging, 2015 Apr 09; 42(5). PMID: 25850931    Free PMC article.
Highly Cited.
Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Brian David Lehmann, Yan Ding, +6 authors, Yajun Yi.
BMC Cancer, 2015 Apr 18; 15. PMID: 25886164    Free PMC article.
Role of genetic and molecular profiling in sarcomas.
Scott M Norberg, Sujana Movva.
Curr Treat Options Oncol, 2015 May 06; 16(5). PMID: 25939540
Review.
E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer.
Chao Cheng, Frederick S Varn, Carmen J Marsit.
Mol Cancer Res, 2015 Jun 03; 13(9). PMID: 26032289    Free PMC article.
Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
Gregory Katz, Olivier Romano, +7 authors, Rémy Salmon.
PLoS One, 2015 Jun 19; 10(6). PMID: 26086912    Free PMC article.
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.
J Ribeiro, B Sousa, F Cardoso.
EJC Suppl, 2013 Sep 01; 11(2). PMID: 26217109    Free PMC article.
Review.
Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer.
Fanny Le Du, Ana M Gonzalez-Angulo, +3 authors, Naoto T Ueno.
Clin Breast Cancer, 2015 Aug 04; 15(6). PMID: 26233757    Free PMC article.
Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?
Niamh Conlon, Dara S Ross, +3 authors, Lee K Tan.
Breast J, 2015 Aug 15; 21(5). PMID: 26271749    Free PMC article.
Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.
Suzanne C O'Neill, Claudine Isaacs, +8 authors, Arnold L Potosky.
J Natl Compr Canc Netw, 2015 Oct 21; 13(10). PMID: 26483061    Free PMC article.
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes.
Yehoda M Martei, Jennifer M Matro.
Breast Cancer (Dove Med Press), 2015 Oct 28; 7. PMID: 26504408    Free PMC article.
Review.
Advances in Proteomic Technologies and Its Contribution to the Field of Cancer.
Mehdi Mesri.
Adv Med, 2014 Jan 01; 2014. PMID: 26556407    Free PMC article.
Review.
A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
Michael D Alvarado, Che Prasad, +5 authors, Christos J Markopoulos.
Adv Ther, 2015 Nov 28; 32(12). PMID: 26610383    Free PMC article.
Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.
Claudette Falato, Nicholas P Tobin, +3 authors, Theodoros Foukakis.
Mol Oncol, 2015 Dec 15; 10(4). PMID: 26651914    Free PMC article.
Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*.
Genet Med, 2015 Dec 19; 18(8). PMID: 26681310
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Dennis C Sgroi, Judy-Anne W Chapman, +10 authors, Michael Pollak.
Breast Cancer Res, 2016 Jan 06; 18(1). PMID: 26728744    Free PMC article.
Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer.
Natalia S Tucker, Amy E Cyr, +9 authors, William E Gillanders.
Ann Surg, 2016 Jan 19; 264(6). PMID: 26779976    Free PMC article.
Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score.
Thaer Khoury, Xiao Huang, +3 authors, Mateusz Opyrchal.
Appl Immunohistochem Mol Morphol, 2016 Jan 26; 24(10). PMID: 26808126    Free PMC article.
Implementation of the 21-gene recurrence score test in the United States in 2011.
Julie A Lynch, Brygida Berse, +5 authors, Andrew N Freedman.
Genet Med, 2016 Feb 19; 18(10). PMID: 26890451
The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
Anna Kuchel, Tim Robinson, +8 authors, Jeremy P Braybrooke.
Br J Cancer, 2016 Mar 10; 114(7). PMID: 26954715    Free PMC article.
Application of cancer-associated glycoforms and glycan-binding probes to an in vitro diagnostic multivariate index assay for precise diagnoses of cancer.
Jeong Gu Kang, Jeong-Heon Ko, Yong-Sam Kim.
Proteomics, 2016 Mar 24; 16(24). PMID: 27005968    Free PMC article.
Review.
Signatures of breast cancer metastasis at a glance.
George S Karagiannis, Sumanta Goswami, +2 authors, John S Condeelis.
J Cell Sci, 2016 Apr 17; 129(9). PMID: 27084578    Free PMC article.
Review.
Therapeutic Application of Pharmacogenomics in Oncology.
Yingqi Zhang, Seumsack Dennis Somtakoune, +2 authors, Xiaodong Feng.
AAPS J, 2016 May 15; 18(4). PMID: 27178043
Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 N0 Breast Cancer and Normal Axillary Ultrasound.
Amy E Cyr, Natalia Tucker, +8 authors, William E Gillanders.
J Am Coll Surg, 2016 May 24; 223(2). PMID: 27212005    Free PMC article.
Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.
Anosheh Afghahi, Maya Mathur, +14 authors, Allison W Kurian.
J Oncol Pract, 2016 May 26; 12(6). PMID: 27221993    Free PMC article.
Breast cancer multigene testing trends and impact on chemotherapy use.
G Thomas Ray, Jeanne Mandelblatt, +4 authors, Tracy A Lieu.
Am J Manag Care, 2016 Jun 09; 22(5). PMID: 27266581    Free PMC article.
Pan-Cancer Analyses Reveal Long Intergenic Non-Coding RNAs Relevant to Tumor Diagnosis, Subtyping and Prognosis.
Travers Ching, Karolina Peplowska, +8 authors, Lana X Garmire.
EBioMedicine, 2016 Jun 21; 7. PMID: 27322459    Free PMC article.
The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
Jessica G Cockburn, Robin M Hallett, +5 authors, Anita Bane.
BMC Cancer, 2016 Jul 30; 16. PMID: 27469239    Free PMC article.
Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis.
Zsuzsanna Mihály, Balázs Győrffy.
Microarrays (Basel), 2013 Jan 01; 2(3). PMID: 27605190    Free PMC article.
Review.
Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.
Vida Pourteimoor, Samira Mohammadi-Yeganeh, Mahdi Paryan.
Tumour Biol, 2016 Sep 22; 37(11). PMID: 27651157
Review.
The analytical validation of the Oncotype DX Recurrence Score assay.
Frederick L Baehner.
Ecancermedicalscience, 2016 Oct 13; 10. PMID: 27729940    Free PMC article.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Review.
Estimating the OncotypeDX score: validation of an inexpensive estimation tool.
Anne A Eaton, Catherine E Pesce, +5 authors, Mahmoud El-Tamer.
Breast Cancer Res Treat, 2016 Dec 09; 161(3). PMID: 27928699    Free PMC article.
Incorporate gene signature profiling into routine molecular testing.
Neng Chen.
Appl Transl Genom, 2013 Apr 11; 2. PMID: 27942443    Free PMC article.
Review.
Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences.
Allison W Kurian, Christopher R Friese, +5 authors, Steven J Katz.
JAMA Oncol, 2016 Dec 30; 3(3). PMID: 28033448    Free PMC article.
Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Carlos H Barcenas, Akshara Raghavendra, +10 authors, Debu Tripathy.
Cancer, 2017 Feb 16; 123(13). PMID: 28199747    Free PMC article.
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Bernhard C Pestalozzi, Christoph Tausch, +17 authors, Swiss Group for Clinical Cancer Research (SAKK).
BMC Cancer, 2017 Apr 15; 17(1). PMID: 28407750    Free PMC article.
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.
Terri P McVeigh, Michael J Kerin.
Breast Cancer (Dove Med Press), 2017 Jun 16; 9. PMID: 28615971    Free PMC article.
Review.
Learning from big data: are we undertreating older women with high-risk breast cancer?
Joseph A Sparano, Hyman Muss.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721380    Free PMC article.
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
Valentina I Petkov, Dave P Miller, +21 authors, Steven Shak.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721379    Free PMC article.
Highly Cited.
Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.
Hala Fawzy Mohamed Kamel, Hiba Saeed A Bagader Al-Amodi.
Genomics Proteomics Bioinformatics, 2017 Aug 17; 15(4). PMID: 28813639    Free PMC article.
Review.
Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.
Holly Janes, Marshall D Brown, +2 authors, William E Barlow.
Contemp Clin Trials, 2017 Aug 19; 63. PMID: 28818434    Free PMC article.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +21 authors, Nicky Liebermann.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900633    Free PMC article.
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Eleftherios P Mamounas, Gong Tang, +14 authors, Norman Wolmark.
Breast Cancer Res Treat, 2017 Nov 13; 168(1). PMID: 29128898    Free PMC article.
Molecular Subtypes and Local-Regional Control of Breast Cancer.
Simona Maria Fragomeni, Andrew Sciallis, Jacqueline S Jeruss.
Surg Oncol Clin N Am, 2017 Nov 15; 27(1). PMID: 29132568    Free PMC article.
Review.
The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.
Ling Xin, Yin-Hua Liu, Tracey A Martin, Wen G Jiang.
World J Oncol, 2017 Nov 18; 8(2). PMID: 29147432    Free PMC article.
Review.
Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients.
Ines Zemni, Montassar Ghalleb, +5 authors, Khaled Rahal.
World J Surg Oncol, 2017 Nov 25; 15(1). PMID: 29169398    Free PMC article.
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
R Colomer, I Aranda-López, +7 authors, J Palacios-Calvo.
Clin Transl Oncol, 2017 Dec 24; 20(7). PMID: 29273958    Free PMC article.
Review.
Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
Jonathan Chen, Xian Wu, +2 authors, Himanshu Nagar.
Breast Cancer Res, 2018 Apr 18; 20(1). PMID: 29661221    Free PMC article.
Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.
S Aggarwal, A Vaid, +10 authors, D Doval.
South Asian J Cancer, 2018 May 04; 7(2). PMID: 29721472    Free PMC article.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Frédérique Penault-Llorca, Thomas Filleron, +12 authors, Henri Roché.
BMC Cancer, 2018 May 08; 18(1). PMID: 29728098    Free PMC article.
Genomic Testing in the Management of Early-Stage Breast Cancer.
Sima Ehsani, Kari Braun Wisinski.
J Clin Outcomes Manag, 2017 May 01; 24(5). PMID: 30158821    Free PMC article.
A Machine Learning Approach for the Association of ki-67 Scoring with Prognostic Factors.
E Dirican, E Kiliç.
J Oncol, 2018 Aug 31; 2018. PMID: 30158977    Free PMC article.
RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer-From Cell Line Models to Liquid Biopsies.
Marvin C J Lim, Anne-Marie Baird, +5 authors, Stephen P Finn.
Diagnostics (Basel), 2018 Sep 12; 8(3). PMID: 30200254    Free PMC article.
Review.
Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
Changjun Wang, Yidong Zhou, +9 authors, Qiang Sun.
Cancer Med, 2018 Oct 03; 7(11). PMID: 30277006    Free PMC article.
Panoptic View of Prognostic Models for Personalized Breast Cancer Management.
Geetanjali Saini, Karuna Mittal, +3 authors, Ritu Aneja.
Cancers (Basel), 2019 Sep 11; 11(9). PMID: 31500225    Free PMC article.
Review.
21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes.
Wei Wang, Lin Lin, +11 authors, Kunwei Shen.
Oncol Lett, 2019 Oct 04; 18(4). PMID: 31579428    Free PMC article.
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre, Aurélie Maran-Gonzalez, +6 authors, Séverine Guiu.
Cancer Manag Res, 2019 Dec 19; 11. PMID: 31849525    Free PMC article.
Review.
Reduced expression of SCUBE2 predicts poor prognosis in gastric cancer patients.
Xiao Wang, Rui-Yi Zhong, Xiao-Jun Xiang.
Int J Clin Exp Pathol, 2018 Feb 01; 11(2). PMID: 31938191    Free PMC article.
A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system.
Christine Y Lu, Marc S Williams, +3 authors, Muin J Khoury.
Genet Med, 2017 Aug 11; 20(4). PMID: 28796238
Review.
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Abiola F Ibraheem, David J Press, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2018 Nov 06; 125(2). PMID: 30387876    Free PMC article.
Glycosylation and its implications in breast cancer.
Danielle A Scott, Richard R Drake.
Expert Rev Proteomics, 2019 Jul 18; 16(8). PMID: 31314995    Free PMC article.
Review.
Preexisting Cancer in Transplant Candidates: Time for a Change in Practice?
Greg A Knoll, Steven J Chadban.
Transplantation, 2018 Mar 21; 102(7). PMID: 29557911    Free PMC article.
Optimal Control Theory for Personalized Therapeutic Regimens in Oncology: Background, History, Challenges, and Opportunities.
Angela M Jarrett, Danial Faghihi, +5 authors, Thomas E Yankeelov.
J Clin Med, 2020 May 07; 9(5). PMID: 32370195    Free PMC article.
Review.
Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
T M Aherne, M R Boland, +4 authors, K J Sweeney.
Surg J (N Y), 2020 Jun 25; 6(2). PMID: 32577529    Free PMC article.
A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry.
Barbara L Smith, Anvy Nguyen, +6 authors, Michele A Gadd.
Breast Cancer Res Treat, 2020 Jul 28; 183(3). PMID: 32712878    Free PMC article.
Review.
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Hiroji Iwata, Norikazu Masuda, +19 authors, Yasuo Ohashi.
Breast Cancer Res Treat, 2018 Sep 23; 173(1). PMID: 30242578    Free PMC article.
Radiomics signature on 3T dynamic contrast-enhanced magnetic resonance imaging for estrogen receptor-positive invasive breast cancers: Preliminary results for correlation with Oncotype DX recurrence scores.
Kyung Jin Nam, Hyunjin Park, +3 authors, Jeong Eon Lee.
Medicine (Baltimore), 2019 Jun 07; 98(23). PMID: 31169691    Free PMC article.
Factors That Predict Biological Aggressiveness in Estrogen Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative / Lymph Node-Negative Breast Cancer.
Lauren E Arthur, Ashley H McMann, +4 authors, Ralph L Corsetti.
Ochsner J, 2021 Jan 08; 20(4). PMID: 33408575    Free PMC article.
A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling.
Ainhoa Arana Echarri, Mark Beresford, +6 authors, James E Turner.
Front Immunol, 2021 Feb 19; 11. PMID: 33597950    Free PMC article.
Review.
The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings.
Abdulmohsen Alkushi, Ahmad Omair, +5 authors, Omalkhair Abulkhair.
Cureus, 2021 Mar 20; 13(2). PMID: 33738150    Free PMC article.